Lv1
50 积分 2025-04-17 加入
Anti-IGF-1R antisense oligonucleotide CT102: A promising therapeutic agent for graves' ophthalmopathy
28天前
已关闭
Impact of Teprotumumab on Clinical Practice in Thyroid Eye Disease
29天前
已完结
IGF-1R drugs travel from cancer cradle to Graves'
29天前
已完结
Hearing abnormalities in patients treated with teprotumumab
1个月前
已完结
Efficacy, Safety, and Recurrence in Older Thyroid Eye Disease Patients Undergoing Teprotumumab Treatment
1个月前
已完结
Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials
1个月前
已完结
Treatment of corticosteroid-resistant Graves' orbitopathy with tocilizumab: a single-centre prospective study
1个月前
已完结
Inflammatory Markers in Thyroid Eye Disease: A Meta-Analysis
2个月前
已完结
Thyroid eye disease
2个月前
已完结
皖公网安备34019202002308
